Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Leukemia, Myeloid, Acute 17Myelodysplastic Syndromes 5Mastocytosis, Systemic 2Leukemia, Mast-Cell 2Leukemia 2Congenital Abnormalities 2Aggression 2Rectal Neoplasms 1Neoplasm, Residual 1GATA2 Deficiency 1

Interventions

Fluorouracil 155Oxaliplatin 133Leucovorin 124Capecitabine 90Irinotecan 88Radiotherapy 63Bevacizumab 61Cetuximab 38Folfox protocol 25Panitumumab 21Neoadjuvant Therapy 21Surgical Procedures, Operative 19Chemotherapy, Adjuvant 15Radiation 13Floxuridine 13Erlotinib Hydrochloride 13Early Intervention, Educational 13IFL protocol 11Drug Therapy 11Proctectomy 10Magnetic Resonance Spectroscopy 10Counseling 10Surveys and Questionnaires 8Sorafenib 8Psychiatric Rehabilitation 8Gene Expression Profiling 8Radiotherapy, Intensity-Modulated 7Immunohistochemistry 7Gemcitabine 7Celecoxib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Rectal Neoplasms × midostaurin × Clear all
NCT01282502 2018-12-12

Midostaurin (PKC412) for Locally Advanced Rectal Cancer

Massachusetts General Hospital

Phase 1 Completed
19 enrolled
Gastrointestinal

Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡